-
Mashup Score: 2SNMMI 2025: STARLiT: Stereotactic Body Radiotherapy and 177Lu PSMA-617 in Locally Advanced Prostate Cancer - 6 hour(s) ago
SNMMI 2025 STARLiT trial, stereotactic body radiotherapy (SBRT) plus 177Lu PSMA-617 in patients with locally advanced prostate cancer, ADT +/- abiraterone/prednisone.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0PRECISION Data Platform Reveals mCRPC Treatment Outcomes in Urology Practices - Neal Shore - 10 hour(s) ago
Zachary Klaassen interviews Neal Shore about real-world treatment patterns for mCRPC patients in community urology centers using the PRECISION database. Dr. Shore analyzes data from over 12,000 mCRPC patients across five years, revealing that community urologists show strong preference for sipuleucel-T and radium-223 as first and second-line therapies, followed by ARPIs, with limited taxane use….
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Real-world insights into mCRPC treatment! Dr. Neal Shore @CURCMB and @zklaassen_md discuss data from the PRECISION platform, highlighting treatment outcomes in #urology practices. #WatchNow > https://t.co/RJsJoh2wEx https://t.co/4Q8N3jSgi8
-
-
Mashup Score: 19SNMMI 2025: A Combination of a CD46-Targeted Antibody-Drug Conjugate and a Radioimmunotherapy Agent for the Treatment of Prostate Cancer - 17 hour(s) ago
SNMMI 2025, Prostate Cancer, Radioimmunotherapy Agent, CD46-Targeted Antibody-Drug Conjugate, CD46-Targeted Antibody-Drug Conjugate and a Radioimmunotherapy Agent for the Treatment of Prostate Cancer, anti-CD46 targeted antibody, YS5, [225Ac]Macropa-PEG4-YS5, [89Zr]DFO-YS5, 225Ac-YS5, Actinium-225.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
A combination of a CD46-targeted antibody-drug conjugate and a radioimmunotherapy agent for the treatment of #ProstateCancer. Presentation by @anilbidkar1 @UCSF. #SNMMI25 written coverage by @RKSayyid @USC > https://t.co/HoS4ZDJaRq @SNM_MI #SNMMI2025 https://t.co/G0st92ko5l
-
-
Mashup Score: 8Interdisciplinary GU Cancer Forum 2025: Novel Agents in Metastatic Urothelial Carcinoma - 1 day(s) ago
Interdisciplinary GU Cancer Forum 2025, Metastatic Urothelial Carcinoma, enfortumab vedotin, Nectin-4 antibody drug conjugate, CRB-701, BT8009-100, DURAVELO-1 trial, DURAVELO-2 trial, zelenectide pevedotin, pembrolizumab, zelenectide pevedotin and pembrolizumab, B440.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Interdisciplinary #GUCancerForum 2025: Novel agents in metastatic #UrothelialCarcinoma. Presentation by @DanielPetrylak @YaleMedicine. Written coverage by @zklaassen_md @GACancerCenter > https://t.co/j2IgfvdfvK https://t.co/yKfmpTt4Za
-
-
Mashup Score: 7Interdisciplinary GU Cancer Forum 2025: What is the Optimal Sequence of Treatment for Metastatic Urothelial Carcinoma? - 1 day(s) ago
Interdisciplinary GU Cancer Forum 2025, urothelial carcinoma, Metastatic Urothelial Carcinoma, enfortumab vedotin, advanced urothelial carcinoma when enfortumab vedotin, Optimal Sequence of Treatment for Metastatic Urothelial Carcinoma, pembrolizumab, EV-301 trial, trastuzumab deruxtecan, DESTINY-PanTumor02 trial, THOR trial, erdafitinib, EV-302 trial, carboplatin.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Interdisciplinary #GUCancerForum 2025: What is the optimal sequence of treatment for metastatic #UrothelialCarcinoma? Presentation by @DanielPetrylak @YaleMedicine. Written coverage by @zklaassen_md @GACancerCenter > https://t.co/2gz2p22pXA https://t.co/4kXtp2tjhZ
-
-
Mashup Score: 7Interdisciplinary GU Cancer Forum 2025: The Role of ctDNA in Monitoring Patients with Metastatic Disease - 1 day(s) ago
Interdisciplinary GU Cancer Forum 2025, role of ctDNA in monitoring patients with metastatic disease, tumor-derived DNA, KEYNOTE-361 trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Interdisciplinary #GUCancerForum 2025: The role of ctDNA in monitoring patients with metastatic disease. Presented by @OncHahn @MDAndersonNews. Written coverage by @zklaassen_md @GACancerCenter > https://t.co/JUAlmh7NGB https://t.co/J9OCs5Rpif
-
-
Mashup Score: 13Interdisciplinary GU Cancer Forum 2025: The Role of ctDNA in Selecting Adjuvant Therapy Post-Cystectomy - 1 day(s) ago
Interdisciplinary GU Cancer Forum 2025, role of ctDNA in selecting adjuvant therapy post-cystectomy, pelvic lymph node dissection for invasive bladder cancer.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Interdisciplinary #GUCancerForum 2025: The role of ctDNA in selecting adjuvant therapy post-cystectomy. Presentation by @GBratslavsky @UpstateNews. Written coverage by @zklaassen_md @GACancerCenter > https://t.co/iB1WYNZkcW https://t.co/1nVZCG4iVJ
-
-
Mashup Score: 9Interdisciplinary GU Cancer Forum 2025: New Approaches to Neoadjuvant Therapy for Urothelial Carcinoma - 1 day(s) ago
urothelial carcinoma, muscle invasive bladder cancer (MIBC), NIAGARA trial, perioperative immune checkpoint inhibitor, durvalumab, enfortumab vedotin, KEYNOTE-905/EV-303 trial, VOLGA trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Interdisciplinary #GUCancerForum 2025: New approaches to neoadjuvant therapy for #UrothelialCarcinoma. Presented by @DanielPetrylak @YaleCancer. Written coverage by @zklaassen_md @GACancerCenter https://t.co/xayLYslOPM https://t.co/aqGKA04HNm
-
-
Mashup Score: 6Interdisciplinary GU Cancer Forum 2025: Clinical Trial Design for the Treatment of NMIBC - 1 day(s) ago
non muscle invasive bladder cancer (NMIBC), Bacillus Calmette-Guérin (BCG) therapy, BCG unresponsive disease.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Interdisciplinary #GUCancerForum 2025: Clinical trial design for the treatment of #NMIBC. Presented by @bbmdmsk @MSKCancerCenter. Written coverage by @zklaassen_md @GACancerCenter > https://t.co/1KhNFPBcyX https://t.co/e3HZwGPthv
-
-
Mashup Score: 22
Interdisciplinary GU Cancer Forum 2025, non muscle invasive bladder cancer (NMIBC), Novel Agents in NMIBC, EV-104 trial, SunRISe bladder trials, TAR-200, BOND-003 trial, CREST Trial, sasanlimab, Bacillus Calmette-Guérin (BCG) therapy, BCG unresponsive non muscle invasive bladder cancer.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Interdisciplinary #GUCancerForum 2025: Novel agents in #NMIBC. Presentation by @LeonardGomella @JeffersonUniv. Written coverage by @chavarriagaj @UofT on UroToday > https://t.co/5nQg2ULnY0 https://t.co/xADxf3gmct
-
#SNMMI25: #STARLiT: Stereotactic body radiotherapy and 177Lu PSMA-617 in locally advanced #ProstateCancer. Presentation by @angela_jia_ @RadOncUH. Written coverage by @RKSayyid @USC > https://t.co/HeyYq26jQI @SNM_MI #SNMMI2025 https://t.co/PfAIJOvb5w